Skip to main content
Top
Published in: BMC Nephrology 1/2021

Open Access 01-12-2021 | Multiple Myeloma | Case report

Light chain deposition disease involving kidney and liver in a patient with IgD myeloma

Authors: Takafumi Tsushima, Tomo Suzuki, Toshiki Terao, Daisuke Miura, Kentaro Narita, Masami Takeuchi, Akira Shimuzu, Kosei Matsue

Published in: BMC Nephrology | Issue 1/2021

Login to get access

Abstract

Background

IgD multiple myeloma (MM) is a rare subtype of MM and light chain deposition disease (LCDD) outside the kidney is also a rare and has scarcely been reported. We report herein the details of the first reported case of LCDD involving the kidney and liver co-occurring with IgD myeloma.

Case presentation

A 66-year-old female with IgD MM presented with rapidly progressive acute renal failure, ascites and pleural effusion. Immunofluorescent study of revealed the characteristic linear deposition of Igκ light chain along the glomerular and tubular basement membrane in kidney. Electron microscopy showed the powdery electron-dense deposits along the tubular and glomerular basement membrane consistent with the diagnosis of LCDD. Laser microdissection followed by mass spectrometry identified only Igκ light chain with more than 95% probability confirm the diagnosis of κ-LCDD but not heavy/light chain deposition disease. Liver biopsy with immunofluorescence study revealed the linear deposition of Igκ chain along the perisinusoidal space indicating the hepatic involvement of κ-LCDD. The patient was successfully treated with combination therapy with bortezomib, cyclophosphamide, dexamethasone, and daratumumab.

Conclusions

This report emphasizes that prompt biopsy of affected organs and initiation of clone directed therapy led to the correct diagnosis and favorable outcome in patient with LCDD who has extrarenal involvement.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lin J, Markowitz GS, Valeri AM, Kambham N, Sherman WH, Appel GB, et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol. 2001;12(7):1482–92.PubMed Lin J, Markowitz GS, Valeri AM, Kambham N, Sherman WH, Appel GB, et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol. 2001;12(7):1482–92.PubMed
2.
go back to reference Sethi S, Rajkumar SV, D'Agati VD. The complexity and heterogeneity of monoclonal immunoglobulin-associated renal diseases. J Am Soc Nephrol. 2018;29(7):1810–23.CrossRef Sethi S, Rajkumar SV, D'Agati VD. The complexity and heterogeneity of monoclonal immunoglobulin-associated renal diseases. J Am Soc Nephrol. 2018;29(7):1810–23.CrossRef
3.
go back to reference Pozzi C, D'Amico M, Fogazzi GB, Curioni S, Ferrario F, Pasquali S, et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis. 2003;42(6):1154–63.CrossRef Pozzi C, D'Amico M, Fogazzi GB, Curioni S, Ferrario F, Pasquali S, et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis. 2003;42(6):1154–63.CrossRef
4.
go back to reference Nasr SH, Valeri AM, Cornell LD, Fidler ME, Sethi S, D'Agati VD, et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol. 2012;7(2):231–9.CrossRef Nasr SH, Valeri AM, Cornell LD, Fidler ME, Sethi S, D'Agati VD, et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol. 2012;7(2):231–9.CrossRef
5.
go back to reference Sayed RH, Wechalekar AD, Gilbertson JA, Bass P, Mahmood S, Sachchithanantham S, et al. Natural history and outcome of light chain deposition disease. Blood. 2015;126(26):2805–10.CrossRef Sayed RH, Wechalekar AD, Gilbertson JA, Bass P, Mahmood S, Sachchithanantham S, et al. Natural history and outcome of light chain deposition disease. Blood. 2015;126(26):2805–10.CrossRef
6.
go back to reference Gavriatopoulou M, Musto P, Caers J, Merlini G, Kastritis E, van de Donk N, et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia. 2018;32(9):1883–98.CrossRef Gavriatopoulou M, Musto P, Caers J, Merlini G, Kastritis E, van de Donk N, et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia. 2018;32(9):1883–98.CrossRef
7.
go back to reference Blade J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol. 1994;12(11):2398–404.CrossRef Blade J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol. 1994;12(11):2398–404.CrossRef
8.
go back to reference Kim MK, Suh C, Lee DH, Min CK, Kim SJ, Kim K, et al. Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients. Ann Oncol. 2011;22(2):411–6.CrossRef Kim MK, Suh C, Lee DH, Min CK, Kim SJ, Kim K, et al. Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients. Ann Oncol. 2011;22(2):411–6.CrossRef
9.
go back to reference Royal V, Quint P, Leblanc M, LeBlanc R, Duncanson GF, Perrizo RL, et al. IgD heavy-chain deposition disease: detection by laser microdissection and mass spectrometry. J Am Soc Nephrol. 2015;26(4):784–90.CrossRef Royal V, Quint P, Leblanc M, LeBlanc R, Duncanson GF, Perrizo RL, et al. IgD heavy-chain deposition disease: detection by laser microdissection and mass spectrometry. J Am Soc Nephrol. 2015;26(4):784–90.CrossRef
10.
go back to reference Joly F, Cohen C, Javaugue V, Bender S, Belmouaz M, Arnulf B, et al. Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study. Blood. 2019;133(6):576–87.CrossRef Joly F, Cohen C, Javaugue V, Bender S, Belmouaz M, Arnulf B, et al. Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study. Blood. 2019;133(6):576–87.CrossRef
11.
go back to reference Mohan M, Buros A, Mathur P, Gokden N, Singh M, Susanibar S, et al. Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. Am J Hematol. 2017;92(8):739–45.CrossRef Mohan M, Buros A, Mathur P, Gokden N, Singh M, Susanibar S, et al. Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. Am J Hematol. 2017;92(8):739–45.CrossRef
12.
go back to reference Samanez C, Domingo A, Cibeira MT, Miquel R, Soler M, Blade J. Development of rapidly progressive liver light chain deposition under VAD chemotherapy in multiple myeloma. Eur J Haematol. 2006;76(1):83–5.CrossRef Samanez C, Domingo A, Cibeira MT, Miquel R, Soler M, Blade J. Development of rapidly progressive liver light chain deposition under VAD chemotherapy in multiple myeloma. Eur J Haematol. 2006;76(1):83–5.CrossRef
13.
go back to reference Cristino A, Pais C, Silva R, Carrola P. Light-chain deposition disease with prominent hepatic involvement. Eur J Case Rep Intern Med. 2017;4(3):000545.PubMedPubMedCentral Cristino A, Pais C, Silva R, Carrola P. Light-chain deposition disease with prominent hepatic involvement. Eur J Case Rep Intern Med. 2017;4(3):000545.PubMedPubMedCentral
14.
go back to reference Cohen C, Royer B, Javaugue V, Szalat R, El Karoui K, Caulier A, et al. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney Int. 2015;88(5):1135–43.CrossRef Cohen C, Royer B, Javaugue V, Szalat R, El Karoui K, Caulier A, et al. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney Int. 2015;88(5):1135–43.CrossRef
15.
go back to reference Petrakis I, Stylianou K, Mavroeidi V, Vardaki E, Stratigis S, Stratakis S, et al. Biopsy-proven resolution of renal light-chain deposition disease after autologous stem cell transplantation. Nephrol Dial Transplant. 2010;25(6):2020–3.CrossRef Petrakis I, Stylianou K, Mavroeidi V, Vardaki E, Stratigis S, Stratakis S, et al. Biopsy-proven resolution of renal light-chain deposition disease after autologous stem cell transplantation. Nephrol Dial Transplant. 2010;25(6):2020–3.CrossRef
16.
go back to reference Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126(5):612–5.CrossRef Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126(5):612–5.CrossRef
17.
go back to reference Roussel M, Merlini G, Chevret S, Arnulf B, Stoppa AM, Perrot A, et al. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis. Blood. 2020;135(18):1531–40.CrossRef Roussel M, Merlini G, Chevret S, Arnulf B, Stoppa AM, Perrot A, et al. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis. Blood. 2020;135(18):1531–40.CrossRef
18.
go back to reference Milani P, Basset M, Curci P, Foli A, Rizzi R, Nuvolone M, et al. Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function. Blood Adv. 2020;4(7):1321–4.CrossRef Milani P, Basset M, Curci P, Foli A, Rizzi R, Nuvolone M, et al. Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function. Blood Adv. 2020;4(7):1321–4.CrossRef
Metadata
Title
Light chain deposition disease involving kidney and liver in a patient with IgD myeloma
Authors
Takafumi Tsushima
Tomo Suzuki
Toshiki Terao
Daisuke Miura
Kentaro Narita
Masami Takeuchi
Akira Shimuzu
Kosei Matsue
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2021
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-021-02246-9

Other articles of this Issue 1/2021

BMC Nephrology 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.